Positive data from AstraZeneca's MIRANDA trial follows the OBERON and TITANIA studies of tozorakimab in COPD.
The post AstraZeneca’s COPD drug gains third Phase III win appeared first on Clinical Trials Arena.
التوازن الغذائي لا يحدد فقط قدرة الجسم على مقاومة الأمراض، بل يؤثر أيضًا على احتمالات حدوث التهابات مزمنة أو اضطرابات مناعية.
Why targeted diversification across therapeutic areas will serve stakeholders and patients better The post The Biosimilar Market Isn’t Failing, It’s Finding Its Purpose appeared first on …
While AI makes VC faster, it’s not necessarily wiser. In healthcare, where breakthroughs rarely resemble anything the market has seen before, that distinction is everything. The …